Cord Blood News Volume 4.46 | Nov 22 2012

Expression of Integrin A2 Receptor in Human Cord Blood Cd34+Cd38-Cd90+ Stem Cells Engrafting Long-Term in Nod/Scid-Il2rγ_CNull Mice
Scientists report that primitive cord blood CD34+CD38-CD90+ stem cells, with the ability to reconstitute NOD/SCID-IL2Rγ_cnull mice long term, at 24 weeks after transplantation, can be prospectively isolated at an increased purity by using integrin α2 receptor as an additional stem cell marker. [Stem Cells] Abstract

Late Outgrowth Endothelial Cells Resemble Mature Endothelial Cells and Are Not Derived from Bone Marrow
Investigators aimed to identify the source and precursor of endothelial outgrowth cells (EOC) and to assess their regenerative potential compared to mature endothelial cells. EOC are readily isolated from umbilical cord blood (6/6 donors) and peripheral blood mononuclear cells (4/6 donors), but not from bone marrow (0/6) nor peripheral blood following mobilization with granulocyte-colony stimulating factor (0/6 donors). [Stem Cells] Abstract

MicroRNA-140 Expression during Chondrogenic Differentiation of Equine Cord Blood-Derived Mesenchymal Stromal Cells
Scientists investigated the expression of microRNA-140 during chondrogenic differentiation of equine cord blood derived mesenchymal stromal cells. [Stem Cells Dev] Abstract

Cord Blood-Derived Mesenchymal Stromal Cells Down-Modulate CD4+ T-Cell Activation by Inducing IL-10 Producing Th1 Cells
Investigators showed by a combination of PCR array, flow cytometry and multiplex cytokine data analysis that during the inhibition of an alloantigen-driven CD4+ T-cell response, mesenchymal stromal cells induce a fraction of CD4+ T-cells to co-express IFNγ and IL-10. [Stem Cells Dev] Abstract

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Promote Vascular Growth In Vivo
Researchers examined the acquisition of properties associated with vascular growth by human umbilical cord blood-derived mesenchymal stem cells, and whether they promoted vascular growth in vivo. [PLoS One]
Full Article

Adhesion of Endothelial Cells and Endothelial Progenitor Cells on Peptide Linked Polymers in Shear Flow
The initial adhesion of human umbilical vein endothelial cells, cord blood endothelial colony forming cells and human blood outgrowth endothelial cells was studied under radial flow conditions. [Tissue Eng Part A] Abstract

Factors with an Impact on Chimerism Development and Long-Term Survival after Umbilical Cord Blood Transplantation
The authors performed a retrospective single-center analysis of 50 umbilical cord blood transplantations (UCBTs), including 37 single and 13 double UCBTs. [Transplantation] Abstract | Video

Long Term Effects of the Implantation of Wharton’s Jelly-Derived Mesenchymal Stem Cells from the Umbilical Cord for Newly-Onset Type 1 Diabetes Mellitus
Researchers assessed the long-term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset Type 1 Diabetes Mellitus. [Endocr J] Abstract | Full Article

The Antitumor Effect of Human Cord Blood-Derived Dendritic Cells Modified by the Livin α Gene in Lung Cancer Cell Lines
Researchers used umbilical cord blood-derived dendritic cells infected with a recombinant adenovirus encoding the livin gene as a vaccine to activate effector cells such as cytotoxic T lymphocytes to recognize and kill livin-expressing cancer cells in vitro as an improved strategy for overcoming the ability of these cancer cells to escape apoptosis and antitumor immune responses. [Oncol Rep] Abstract

UC-Davis and StemCyte Announce Cord Blood Banking Partnership
StemCyte, Inc. announced an agreement with the UC Davis Umbilical Cord Blood Collection Program in Sacramento to advance the collection, processing and registration of high quality and diverse cord blood cells from California mothers for public banking. [StemCyte, Inc.] Press Release

Biosafe’s Sepax System Receives Chinese SFDA Approval
Biosafe Group SA announced that it has obtained Chinese SFDA registration for its Sepax® device, completing its worldwide registration program. Biosafe’s flagship Sepax cell separation technology is a versatile platform dedicated to adult stem cell processing, addressing major medical markets such as cord blood banking, stem cell transplantation and regenerative medicine. [Biosafe Group SA] Press Release

Stem Cell Pioneer Recognized for 20 Years of Discovery and Innovation
Dr. David Harris was the recipient of the Arizona BioIndustry Association™ 2012 award for “20 Years of Discovery and Innovation”. In 1991, Dr. Harris became the first person to bank stem cells for future use. He did so by banking his first child’s cord blood stem cells. In 1992, Dr. Harris founded the Arizona Cord Blood Bank which later evolved to become the Cord Blood Registry™. [PR Newswire Association LLC]
Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

View our events page to see a complete list of events in the cord blood community.

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Quality Control Analyst (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Research Associate in Stem Cell Biology – Cardiovascular Regeneration (CReATe Fertility Centre)

Senior Research Technologist – Hematology (St. Jude Children’s Research Hospital)

Postdoctoral Fellow in Stem Cell Biology (University of Texas Medical School at Houston)

Senior Research Fellowships (Josep Carreras Leukaemia Research Institute)

Postdoctoral Position (BloodCenter of Wisconsin)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.